Sourasky Medical Center (Ichilov)
| イスラエル | トルコ | オーストリア | |
| 生物学的療法 | - | から $5,500 | から $20,000 |
この医師は化学療法と放射線療法の専門家であり、乳がん、子宮がん、前立腺がん、消化管がん、肺がん、腎臓がん、膀胱がんを含む様々な腫瘍性疾患の治療に焦点を当てています。医師は化学療法、放射線療法、生物学的がん治療などの先進的な治療法を用い、がん治療後のリハビリテーションも提供しています。
1988年からの経験を持ち、2009年からSourasky (Ichilov) Medical Centerで上級腫瘍専門医として勤務しており、Rambam Medical CenterおよびSourasky Medical Centerで重要な役職を歴任しています。医師は30以上の科学論文に貢献しており、がん治療の臨床試験にも関与しています。
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Prof. Amit Tirosh is a senior endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He specializes in neuroendocrine tumors (NETs).
His work centers on hereditary NET syndromes. He is affiliated with the NIH in MEN1 research. He serves on an international VHL expert panel and helped write VHL management guidelines. He is the primary contact at Sheba’s multidisciplinary VHL clinic.
He leads the Endocrine Oncology Bioinformatics Lab. He collaborates with international teams, including the Weizmann Institute. He provides advanced NET care, including PRRT.
He earned his MD from the Hebrew University–Hadassah. He completed a residency at Assaf HaRofeh, an endocrinology fellowship at Rabin, and training at the NIH. He is board-certified in Endocrinology. He is a member of the Israeli Society of Endocrinology, the Endocrine Society, and the European Neuroendocrine Tumor Society. He has authored over 40 peer-reviewed papers, including in JAMA, Gastroenterology, and Radiology.